Company Leadership Changes - PharmaLogic Holdings Corp. appointed Etienne Montagut as President and Chief Executive Officer effective June 1, 2025 [1] - Steve Chilinski, who led the company for 13 years, retired as CEO and will take on the role of Executive Chairman of the Board [3] Leadership Experience - Etienne Montagut has over 25 years of senior leadership experience in the pharmaceutical sector, with a proven track record in driving growth and executing strategic transformations globally [2] Company Overview - PharmaLogic is a leading global contract development and manufacturing organization (CDMO) specializing in diagnostic and therapeutic radiopharmaceuticals [4] - The company operates more than 45 facilities across the U.S., Puerto Rico, Canada, and Norway, providing comprehensive solutions for the development, manufacturing, and distribution of radiopharmaceutical products [4] Business Segments - The diagnostics business is rapidly expanding, utilizing advanced technologies to improve patient access to novel diagnostics in oncology, cardiology, and Alzheimer's disease [5] - PharmaLogic is the only cGMP-compliant CDMO manufacturing and distributing a commercial radiopharmaceutical therapeutic in over 30 countries [5] Strategic Focus - The company is dedicated to enhancing global patient access to radiopharmaceuticals through strategic development partnerships with industry innovators [6]

Group 1 - IBA has initiated a share buyback program to repurchase up to 650,000 ordinary shares to fulfill obligations under long-term incentive plans for management and certain personnel [2][3] - The company repurchased a total of 16,651 shares between May 27 and May 28, 2025, at an average price of €12.19 per share, totaling €203,014.21 [3] - The total number of treasury shares held by IBA amounts to 1,015,552, representing 3.35% of total issued shares, which are 30,282,218 [3] Group 2 - IBA is a leader in particle accelerator technology, specializing in proton therapy, industrial sterilization, radiopharmaceuticals, and dosimetry [4] - The company is based in Louvain-la-Neuve, Belgium, and employs approximately 2,100 people globally [4] - IBA is listed on the pan-European stock exchange EURONEXT [5]